The Value of H3K27me3 Immunohistochemistry in Differentiating Malignant Peripheral Nerve Sheath Tumour with Its Histologic Mimickers

Mustapar, N; Zawawi, Muhamad Syahrul Fitri; Sharif, Sharifah Emilia Tuan

doi:10.31557/apjcp.2020.21.3.699

Cited by 8 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Staining intensity was graded on a 0-3 scale: 0, absence of staining; 1, weakly stained; 2, moderately stained; and 3, intensely stained. The percentage of positive tumor cells was scored as follows: 0, absence of tumor cells; 1, <33% of tumor cells; 2, 33-66% of tumor cells; and 3, >66% of tumor cells (Mustapar et al, 2020).…”

Section: Immunochemistrymentioning

confidence: 99%

KDF1 Promoted Proliferation and Metastasis of Epithelial Ovarian Cancer via Wnt/Beta-Catenin Pathway: TCGA-Based Data Mining and Experimental Validation

et al. 2022

View full text Add to dashboard Cite

Objectives: It has been reported that keratinocyte differentiation factor 1 (KDF1) was related to proliferation, differentiation, and cell cycle. However, the role of KDF1 has not been reported in ovarian cancer. The present study investigated the function and the potential mechanism of KDF1 in ovarian cancer.Methods: We evaluated the prognostic value in ovarian cancer based on data from the Cancer Genome Atlas (TCGA) database. The Kruskal–Wallis test, Wilcoxon signed-rank test, and logistic regression were used to evaluate the relationship between KDF1 expression and clinicopathologic features. The Cox regression and the Kaplan–Meier method were adopted to evaluate prognosis-related factors. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) gene enrichment analysis, and Gene Set Enrichment Analysis (GSEA) were performed to identify the key biological process related to KDF1. Then the expression of KDF1 in ovarian cancer tissues was validated by streptavidin–peroxidase (SP) immunohistochemistry. The proliferation and invasion ability of KDF1 were determined by EdU and Transwell assay, respectively, with KDF1 gene silencing and overexpression. The mRNA expression of KDF1 was determined by qPCR. The protein expression of KDF1 was determined using the Western blot.Methods: By performing differential expression analysis on the ovarian cancer data of the TCGA database, it was found that KDF1 is highly expressed in ovarian cancer patients and associated with poorer overall survival (OS) and progression-free survival (PFS) of ovarian cancer patients. The highly expressed KDF1 may reduce cell adhesion according to GO, KEGG, and GSEA results. After analysis combining the relevant clinical features, we found that the high expression of KDF1 is an independent prognostic factor of ovarian cancer and associated with platinum resistance and tumor metastasis in ovarian cancer. At the same time, the BioGRID database showed that there might be protein–protein interaction between KDF1 and E-cadherin. Then we further validated that the high expression of KDF1 had a close correlation with the stage and grade of ovarian cancer in ovarian cancer tissue chips. Silencing KDF1 inhibited the proliferation and invasion ability of SKOV3 cells. By contrast, ectopic expression of KDF1 promoted the proliferation and invasion ability of A2780 cells. We also found that KDF1 can interact with E-cadherin and regulate the expression of Wnt5A and β-catenin, hence activating Wnt/β-catenin pathway via in vitro and vivo experiments.Conclusions: Based on the bioinformatics analysis, in vitro experiments, and an in vivo study, it is indicated that KDF1 played an important role in ovarian cancer progression and might be a therapeutic target for patients with ovarian cancer.

show abstract

Section: Immunochemistrymentioning

confidence: 99%

KDF1 Promoted Proliferation and Metastasis of Epithelial Ovarian Cancer via Wnt/Beta-Catenin Pathway: TCGA-Based Data Mining and Experimental Validation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It is also useful in differentiating between ANNUBP and MPNST as it is not lost in AN-NUBP. 8 Since our case showed positivity to the S-100 protein and was associated with NF1, we considered there was no need to do the H3K27me3 staining.…”

Section: Discussionmentioning

confidence: 80%

“…In our case, there was focal positivity for S-100 staining, although S-100 may show decreased sensitivity for MPNST. 8 The current most specific marker of MPNST is the loss of H3K27me3 (trimethylated histone 3 at lysine residue 27), which has been reported to occur in 61% of MPNST cases, including those associated with NF1. It is also useful in differentiating between ANNUBP and MPNST as it is not lost in AN-NUBP.…”

Section: Discussionmentioning

confidence: 99%

Malignant peripheral nerve sheath tumor with rhabdoid features arising in the temporal region of a patient suffering from neurofibromatosis 1 – A case report

Amer¹,

Shaheen²,

Ashoub³

et al. 2022

j.rpemd

View full text Add to dashboard Cite

The malignant peripheral nerve sheath tumor is one of the rare sarcomas that have a challenging diagnosis. It occurs independently with neurofibromatosis type 1. Some studies referred that malignant peripheral nerve sheath tumor attains a worse prognosis when it occurs in the head and neck region. In the reported case, a male patient with neurofibromatosis type 1 manifestations presented with a large mass in the temporal region. Based on the clinical history, histopathology, and immunohistochemical findings, the lesion was diagnosed as a low-grade malignant peripheral nerve sheath tumor with rhabdoid features. Surgical resection followed by intensity-modulated radiotherapy was the treatment of choice.

show abstract

“…Additionally, the loss of staining with the antibody H3K27me3 is a new sensitive and specific marker for conventional high grade MPNST ( Figure 3 d). However, retained staining can also be seen in lower grade tumors [ 50 , 51 , 52 ]. H3K27me3 is an epigenetic DNA packaging protein that modifies histone H3 by tri-methylating the 27th lysine residue.…”

Section: Malignant Peripheral Nerve Sheath Tumor (Mpnst)mentioning

confidence: 99%

Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma

Mack

Purgina

2022

Current Oncology

View full text Add to dashboard Cite

Retroperitoneal tumors are extremely rare. More than 70% of primary retroperitoneal soft tissue tumors are malignant. The most common sarcomas in the retroperitoneum include liposarcomas and leiomyosarcoma, however other sarcomas, along with benign mesenchymal tumors, can occur. Sarcomas are a heterogenous group of tumors with overlapping microscopic features, posing a diagnostic challenge for the pathologist. Correct tumor classification has become important for prognostication and the evolving targeted therapies for sarcoma subtypes. In this review, the pathology of retroperitoneal soft tissue sarcomas is discussed, which is important to the surgical oncologist. In addition, less common sarcomas and benign mesenchymal tumors of the retroperitoneum, which may mimic sarcoma clinically and pathologically, are also discussed.

show abstract

The Value of H3K27me3 Immunohistochemistry in Differentiating Malignant Peripheral Nerve Sheath Tumour with Its Histologic Mimickers

Cited by 8 publications

References 22 publications

KDF1 Promoted Proliferation and Metastasis of Epithelial Ovarian Cancer via Wnt/Beta-Catenin Pathway: TCGA-Based Data Mining and Experimental Validation

KDF1 Promoted Proliferation and Metastasis of Epithelial Ovarian Cancer via Wnt/Beta-Catenin Pathway: TCGA-Based Data Mining and Experimental Validation

Malignant peripheral nerve sheath tumor with rhabdoid features arising in the temporal region of a patient suffering from neurofibromatosis 1 – A case report

Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma

Contact Info

Product

Resources

About